Unicycive Therapeutics Past Earnings Performance
Past criteria checks 0/6
Unicycive Therapeutics's earnings have been declining at an average annual rate of -60.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 79.4% per year.
Key information
-60.1%
Earnings growth rate
-45.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 79.4% |
| Return on equity | n/a |
| Net Margin | -4,653.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18Revenue & Expenses BreakdownBeta
How Unicycive Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -31 | 9 | 13 |
| 30 Sep 23 | 1 | -29 | 8 | 13 |
| 30 Jun 23 | 2 | -30 | 7 | 14 |
| 31 Mar 23 | 2 | -29 | 7 | 14 |
| 31 Dec 22 | 1 | -18 | 7 | 12 |
| 30 Sep 22 | 1 | -15 | 6 | 10 |
| 30 Jun 22 | 0 | -15 | 6 | 9 |
| 31 Mar 22 | 0 | -13 | 4 | 8 |
| 31 Dec 21 | 0 | -10 | 3 | 6 |
| 30 Sep 21 | 0 | -8 | 2 | 5 |
| 30 Jun 21 | 0 | -4 | 1 | 2 |
| 31 Mar 21 | 0 | -3 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 30 Sep 20 | 0 | -2 | 1 | 1 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | -2 | 1 | 1 |
| 31 Dec 19 | 0 | -2 | 1 | 1 |
Quality Earnings: UNCY is currently unprofitable.
Growing Profit Margin: UNCY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UNCY is unprofitable, and losses have increased over the past 5 years at a rate of 60.1% per year.
Accelerating Growth: Unable to compare UNCY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UNCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: UNCY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.